| Phase 17 trials |
|
Phase 1
|
NCT07594847 |
Mar → Sep 2026 expected |
— |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07331389 |
Sep 2025 → Jan 2026 overdue |
— |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06985615 |
Mar 2025 → Jan 2026 overdue |
— |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06601517 |
Oct 2024 → Feb 2025 overdue |
— |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06608329 |
Oct → Nov 2024 overdue |
— |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06576401 |
Aug → Oct 2024 overdue |
— |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06562088 |
Aug → Nov 2024 overdue |
— |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT06500299 |
Jul → Oct 2024 |
— |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT06481085 |
Jun 2024 → May 2025 |
type 2 diabetes mellitus |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT07193459 |
Aug 2025 → Oct 2026 expected |
type 2 diabetes mellitus |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07082114 |
Jul 2025 → Feb 2027 expected |
type 2 diabetes mellitus |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06885021 |
Mar 2025 → May 2026 overdue |
— |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|